246 related articles for article (PubMed ID: 32920226)
1. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis.
Podszun MC; Alawad AS; Lingala S; Morris N; Huang WA; Yang S; Schoenfeld M; Rolt A; Ouwerkerk R; Valdez K; Umarova R; Ma Y; Fatima SZ; Lin DD; Mahajan LS; Samala N; Violet PC; Levine M; Shamburek R; Gharib AM; Kleiner DE; Garraffo HM; Cai H; Walter PJ; Rotman Y
Redox Biol; 2020 Oct; 37():101710. PubMed ID: 32920226
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
[TBL] [Abstract][Full Text] [Related]
4. Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose.
Tian H; Fang Y; Liu W; Wang J; Zhao J; Tang H; Yin Y; Hu Y; Peng J
J Ethnopharmacol; 2023 Jan; 301():115806. PubMed ID: 36216198
[TBL] [Abstract][Full Text] [Related]
5. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
[TBL] [Abstract][Full Text] [Related]
6. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
7. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
8. Baicalein Enhances the Effect of Acarbose on the Improvement of Nonalcoholic Fatty Liver Disease Associated with Prediabetes via the Inhibition of
Xing Y; Ren X; Li X; Sui L; Shi X; Sun Y; Quan C; Xiu Z; Dong Y
J Agric Food Chem; 2021 Sep; 69(34):9822-9836. PubMed ID: 34406004
[TBL] [Abstract][Full Text] [Related]
9. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.
Steensels S; Qiao J; Zhang Y; Maner-Smith KM; Kika N; Holman CD; Corey KE; Bracken WC; Ortlund EA; Ersoy BA
Hepatology; 2020 Sep; 72(3):857-872. PubMed ID: 32498134
[TBL] [Abstract][Full Text] [Related]
10. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F
Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449
[TBL] [Abstract][Full Text] [Related]
11. Long-term exposure to high-sucrose diet down-regulates hepatic endoplasmic reticulum-stress adaptive pathways and potentiates de novo lipogenesis in weaned male mice.
Flister KFT; Pinto BAS; França LM; Coêlho CFF; Dos Santos PC; Vale CC; Kajihara D; Debbas V; Laurindo FRM; Paes AMA
J Nutr Biochem; 2018 Dec; 62():155-166. PubMed ID: 30300835
[TBL] [Abstract][Full Text] [Related]
12. Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.
Green CJ; Marjot T; Walsby-Tickle J; Charlton C; Cornfield T; Westcott F; Pinnick KE; Moolla A; Hazlehurst JM; McCullagh J; Tomlinson JW; Hodson L
Eur J Endocrinol; 2022 Feb; 186(3):367-377. PubMed ID: 35038311
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.
Paglialunga S; Dehn CA
Lipids Health Dis; 2016 Sep; 15(1):159. PubMed ID: 27640119
[TBL] [Abstract][Full Text] [Related]
14. Nutritional regulation of hepatic de novo lipogenesis in humans.
Cross E; Dearlove DJ; Hodson L
Curr Opin Clin Nutr Metab Care; 2023 Mar; 26(2):65-71. PubMed ID: 36892956
[TBL] [Abstract][Full Text] [Related]
15. Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis.
Buyl K; Vrints M; Fernando R; Desmae T; Van Eeckhoutte T; Jans M; Van Der Schueren J; Boeckmans J; Rodrigues RM; De Boe V; Rogiers V; De Kock J; Beirinckx F; Vanhaecke T
Eur J Pharmacol; 2023 Oct; 957():175989. PubMed ID: 37572939
[TBL] [Abstract][Full Text] [Related]
16. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease.
Cohen CC; Li KW; Alazraki AL; Beysen C; Carrier CA; Cleeton RL; Dandan M; Figueroa J; Knight-Scott J; Knott CJ; Newton KP; Nyangau EM; Sirlin CB; Ugalde-Nicalo PA; Welsh JA; Hellerstein MK; Schwimmer JB; Vos MB
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34907907
[TBL] [Abstract][Full Text] [Related]
17. Fructose-induced perturbation in cellular proteostasis via RPS6KB1 promotes hepatic steatosis.
Raza S; Shahi A; Medhe P; Tewari A; Gupta P; Rajak S; Chakravarti B; Sinha RA
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119597. PubMed ID: 37741573
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
Esler WP; Cohen DE
J Hepatol; 2024 Feb; 80(2):362-377. PubMed ID: 37977245
[TBL] [Abstract][Full Text] [Related]
19. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver.
Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.
Zhang C; Lu Y; Song Y; Chen L; Hu J; Meng Y; Chen X; Li S; Zheng G; Qiu Z
J Cell Mol Med; 2022 Jul; 26(14):3995-4006. PubMed ID: 35713152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
